B7-H1 pathway and its role in the evasion of tumor immunity (original) (raw)

References

1. Jantzer P, Schendel DJ (1998) Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 58:3078–3086
   CAS PubMed Google Scholar
2. D'Souza S, Rimoldi D, Lienard D, Lejeune F, Cerottini JC, Romero P (1998) Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int J Cancer 78:699–706
   Article CAS PubMed Google Scholar
3. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677–685
   CAS PubMed Google Scholar
4. Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, Czerniecki BJ, Shu S (2001) T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 21:215–248
   CAS PubMed Google Scholar
5. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B (2002) Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol 23:240–245
   Google Scholar
6. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018–1023
   CAS PubMed Google Scholar
7. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V (1998) Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641–1650
   Article CAS PubMed Google Scholar
8. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM (2000) Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265–276
   CAS PubMed Google Scholar
9. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299
   CAS PubMed Google Scholar
10. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3:999–1005
    Article CAS PubMed Google Scholar
11. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998
    Article CAS PubMed Google Scholar
12. Dong H, Zhu G, Tamada K, Chen L (1999) B7–H1, a third member of the B7 family, costimulates T-cell proliferation and secretion of interleukin-10. Nat Med 5:1365–1369
    Article CAS PubMed Google Scholar
13. Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat JF, Ellis J, Bonnefoy JY (1997) CD86 (B7–2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells. J Biol Chem 272:15613–15619
    Article CAS PubMed Google Scholar
14. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, Tamura H, Driscoll CL, Chen L (2003) Costimulating aberrant T cell responses by B7–H1 autoantibodies in rheumatoid arthritis. J Clin Invest 111:363–370
    Google Scholar
15. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800
    CAS PubMed Google Scholar
16. Petroff MG, Chen L, Phillips TA, Hunt JS (2002) B7 family molecules: novel immunomodulators at the maternal-fetal interface. Placenta [Suppl A]:S95–101
17. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034
    Article CAS PubMed Google Scholar
18. Mazanet MM, Hughes CC (2002) B7–H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169:3581–3588
    CAS PubMed Google Scholar
19. Tamura H, Dong H, Zhu G, Sica GL, Flies DB, Tamada K, Chen L (2001) B7–H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97:1809–1816
    Article CAS PubMed Google Scholar
20. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, Honjo T (2002) Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptorPD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 84:57–62
    Article CAS PubMed Google Scholar
21. Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169:5538–5545
    CAS PubMed Google Scholar
22. Bleul CC, Boehm T (2001) Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product. Eur J Immunol 31:2497–2503
    Article CAS PubMed Google Scholar
23. Gray CP, Arosio P, Hersey P (2002) Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood 99:3326–3334
    Article CAS PubMed Google Scholar
24. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261–268
    Article CAS PubMed Google Scholar
25. Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895
    CAS PubMed Google Scholar
26. Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, Hardy RR, Burrows PD, Billips LG (1997) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 197:177–187
    Article CAS PubMed Google Scholar
27. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, Bolstad AI, Svenungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-Varela J, Jonsson R, Gyllensten UB, Harley JB, Alarcon-Segovia D, Steinsson K (2002) Alarcon-Riquelme ME. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666–669
    Article CAS PubMed Google Scholar
28. Nishimura H, Agata Y, Kawasaki A, Sato M, Imamura S, Minato N, Yagita H, Nakano T, Honjo T (1996) Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 8:773–780
    CAS PubMed Google Scholar
29. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765–772
    CAS PubMed Google Scholar
30. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM (2002) PD-1: PD-L inhibitory pathway affects both CD4 (+) and CD8 (+) T cells and is overcome by IL-2. Eur J Immunol 32:634–643
    Article CAS PubMed Google Scholar
31. Nishimura H, Minato N, Nakano T, Honjo T (1998) Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 10:1563–1572
    Article CAS PubMed Google Scholar
32. Nishimura H, Nose M, Hiai. H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151
    CAS PubMed Google Scholar
33. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322
    Article CAS PubMed Google Scholar
34. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98:13866–13871
    Article CAS PubMed Google Scholar
35. Nishimura H, Honjo T, Minato N (2000) Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med 191:891–898
    Article CAS PubMed Google Scholar
36. Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, Honjo T (2002) Microanatomical localization of PD-1 in human tonsils. Immunol Lett 83:215–220
    Article CAS PubMed Google Scholar
37. Ferrone S, Finerty JF, Jaffee EM, Nabel GJ (2000) How much longer will tumour cells fool the immune system? Immunol Today 21:70–72
    Google Scholar
38. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE (1994) B7–1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 54:5420–5423
    CAS PubMed Google Scholar
39. Sykulev Y, Brunmark A, Tsomides TJ, Kageyama S, Jackson M, Peterson PA, Eisen HN (1994) High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogeneic and syngeneic major histocompatibility complex class I proteins. Proc Natl Acad Sci USA 91:11487–11491
    CAS PubMed Google Scholar
40. Lollini PL, Forni G (1999) Specific and nonspecific immunity in the prevention of spontaneous tumors. Immunol Today 20:347–350
    Google Scholar
41. Sinkovics JG, Horvath JC (2000) Vaccination against human cancers. Int J Oncol 16:81–96
    CAS PubMed Google Scholar
42. Pecher G, Haring A, Kaiser L, Thiel E (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51:669–673
    Article CAS PubMed Google Scholar
43. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854
    Article CAS PubMed Google Scholar
44. Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE (2002) Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 8:343–348
    Article CAS PubMed Google Scholar
45. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L (1997) Monoclonal antibodies against the 4–1BB T-cell activation molecule eradicate established tumors. Nat Med 3:682–685
    CAS PubMed Google Scholar
46. Chambers CA, Kuhns MS, Egen JG, Allison JP (2001) CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565–594
    Google Scholar
47. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297
    Article CAS PubMed Google Scholar

Download references